The ONLY cell therapy conference in Japan which focuses on key topics in manufacturing across cell & gene therapy is back for another year!
Held on 27th-28th February 2020 and bringing together key influencers from pharma and biotech companies across the world, our Cell Therapy Manufacturing Asia Congress will provide you with the latest advice for driving manufacturing and commercialization through direct access to the innovative research transforming cell manufacturing.
This year connect with industry leaders from the brightest minds, locally and beyond...
Date and Time:
27-28 February 2020
Venue:
The Westin Miyako Kyoto
Please register beforehand
(Opens an external site)
※We offer LINK-J Supporters & Members exclusive discount. Contact us and register now.
Program
Thursday, 27 February Day1
| Time | Program |
| 7:15 - 7:55 |
Registration
|
| 7:55 - 8:00 | Conference Opening and Welcome |
| STRATEGIES FOR GLOBAL COMMERCIAL SUCCESS - NOVEL TECH TRANSFER & MANUFACTURING MODELS ACROSS BORDERS | |
| 8:00 - 8:30 | Novartis/ Cellular Biomedicine Case Study - in China Robin Ng, Strategy Lead for Technology and Manufacturing, Cellular Biomedicine Group, China |
| 8:30 - 9:00 | Experience with Yescarta in China Richard Wang, CEO, Fosun Kite, China |
| LATEST DATA & DEVELOPMENTS IN IPSC | |
| 9:00 - 9:30 | Cell Engineering & Organ Replacement • Engineering iPS cells • Cloaking/universal cells linked to iPSc Hardy TS Kagimoto, Chairman and CEO, Healios K.K., Japan |
| 9:30 - 10:00 | Consideration of standard specification and test methods for manufacturing of iPSC-MCB Takafusa Hikichi, Quality Control Unit Manager, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan |
| 10:00 - 10:30 | iPSCs-based Regenerative Medicine and Drug Development for CNS Diseases Hideyuki Okano, Team Leader, Laboratory for Marmoset Neural Architecture, RIKEN Center for Brain Science, Dean, Keio University Graduate School of Medicine, Professor and Chairman, Department of Physiology, Keio University School of Medicine, Japan |
| 10:30 - 11:00 | Morning Coffee and Networking |
| TECHNOLOGIES AND NOVEL PLATFORMS FOR EFFICIENT UPSTREAM AND DOWNSTREAM PROCESSES | |
| 11:00 - 11:30 | Manufacturing technologies for fulfilling the cell and gene therapy needs in Asia Colby Colasanto, Strategic Business Director, Cellogics, Singapore |
| 11:30 - 12:00 | CAR-NK cell line manufacturing Sae Won Kim, Head of Immune Cell Therapy Team, SL BIGEN, South Korea |
| 12:00 - 12:30 |
Spotlight Presentation - PBS Biotech
|
| 12:30 - 1:30 | Lunch and Networking |
| TECHNOLOGIES AND NOVEL PLATFORMS FOR EFFICIENT UPSTREAM AND DOWNSTREAM PROCESSES | |
| 1:30 - 2:00 | Scaling Up MSc and EV Production into Bioreactors Maya Lim, Regional Account Manager, RoosterBio Inc., USA |
| 2:00 - 2:30 | Scale Up Process Development for iPSC Derived Human Immune Cell Therapies Wen Bo Wang, SVP, Technical Operations, Fate Therapeutics, USA |
| 2:30 - 3:00 | Towards fast, accurate and affordable bioprocess control with chip technology Katleen Verleysen, Strategic Partnerships Life Sciences, IMEC, Belgium |
| 3:00 - 3:30 | Refreshment Break in the Exhibition Hall |
| MANUFACTURING AUTOMATION: FROM VEIN TO VEIN | |
| 3:30 - 4:00 | Preparing for commercialization - Evolution in Automation Approaches • Manual -> modular -> integrated -> step change automation • COGs should reduce, and industrialization potential should increase • Finding platforms dedicated to your entire manufacturing process and not just a few process steps • Flexible systems that can be programmed by end users Damian Marshall, Director of New Technologies, Cell and Gene Therapy Catapult, UK |
| ENHANCED QUALITY & CLINICAL TRIAL RESULTS FOR CAR & T CELL PRODUCTS | |
| 4:00 - 4:30 | The Evolving Product Landscape in China - Country Overview • A look at recent clinical trial results in the region • What is the tole between academia & the private sector • Who is leading the field in China? • How are manufacturing sites being developed following on from clinical programs Ting He, CEO, ImmunoChina Pharmaceuticals Co. Ltd., China |
| 4:30 - 5:00 | EutilexCo.Ltd. Introduction of Innovative T cell Therapies: 4-1BB Based Autologous T cell Therapy and MVR • A look at recent clinical trial results in the region • What is the tole between academia & the private sector • Who is leading the field in China? • How are manufacturing sites being developed following on from clinical programs Jeonghoon Han Ph.D. (한정훈), Vice President, Chief Technology Officer, Head of R&D Center, EUTILEX, South Korea |
| 5:00 - 7:00 |
End of Day 1 + Evening Networking
|
Friday, 28 February Day2
| Time | Program |
| 8:15 - 8:40 |
Registration
|
| 8:40 - 8:45 | Conference Opening and Welcome |
| TRANSITIONING TECHNOLOGIES FROM BENCH TO BEDSIDE: CRISPR, CAS9, GENE THERAPY AND MORE | |
| 8:45 - 9:15 | Novel Non-Viral Vector Based CAR-T Platform Development and Progress Update Karen Wen, Chief Strategy and Product Development Officer, GenomeFrontier Therapeutics, Inc., Taiwan |
| 9:15 - 9:45 | ID Pharma Co., Ltd. Case Study - Sendai Virus • Sendai Virus Vector Technology • Application of Sendai Virus Vector to Cell Engineering and Gene Therapy Jitsutaro Kawaguchi, Manager, Department of Cell Engineering, ID Pharma Co., Ltd., Japan |
| PRECISION MANUFACTURING PROCESSES - FACILITY CONSIDERATIONS, MONITORING & DESIGN | |
| 9:45 - 10:15 | Cell Therapy Manufacturing Commercialization - Strategy and Challenges • Unique Manufacturing Challenges for Autologous Cell Therapy • IND to Commercial: A Paradigm Shift • Development By Design • Quality By Design • Cell Therapy COGs Optimization • IND to Commercial: Scale-out Challenge • Cell Therapy Technology Road Map Vision • Current Weakness in the Technology Landscape • Final Thoughts Harry Lam, EVP, Head of Technical Operations, JW Therapeutics (Shanghai) Co., LTD., China |
| 10:15 - 11:00 |
Morning Coffee and Networking
|
| WORKING WITH EXTERNAL PARTNERS TO DRIVE COMMERCIALIZATION | |
| 11:00 - 11:30 | Overview of the Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy - SMaRT Kenji Komeda, Senior Director, SMaRT, Regenerative & Cellular Medicine Manufacturing Plant, Sumitomo Dainippon Pharma Co., Ltd., Japan |
| 11:30 - 12:30 | DISCUSSION PANEL: Outsourcing vs. Insourcing - What is the best path to take? Looking for 3-5 panellists to join this session that will be looking at: • Outsourcing models for cell and gene therapies • Auto vs. allo • What is the best timeline if you are considering outsourcing? • When to make the call and make the move? • Should a CMO be used early phase? Or once you reach submission? • Why wouldn't you outsource? • Are there different solutions dependent on product type? • Does one choice result in a more financially viable product? David W. Smith, Director, Healios K.K., Japan Jeonghoon Han Ph.D. (한정훈), Vice President, Chief Technology Officer, Head of R&D Center, EUTILEX, South Korea Tony Liu, CEO, Cellular Biomedicine Group, China Kim Raineri, VP Operations, Nikon CeLL innovation, Japan |
| 12:30 - 1:00 |
Spotlight Presentation
|
| 1:00 - 2:15 | Lunch and Networking |
| UPSTREAM AND DOWNSTREAM SUPPLY CHAIN CONSIDERATIONS | |
| 2:45 - 3:15 | Perfecting a CAR T Supply Chain What is CAR T Therapy • Supply Chain overview, requirement and challenges • Key Success Factor • End to End Supply Design and Integration • Partnership and Collaboration • Information Technology and Solution • Next Steps and Action Naoki Kitadai, CAR T Supply Chain Lead, Celgene K.K., Japan |
| CELL CHARACTERIZATION - QUALITY CONTROL & ANALYTICAL STRATEGIES | |
| 2:45 - 3:15 | Critical Quality Attributes & Controls for Cell Therapy Products • Case study • AI/Machine Learning specific case study Hidenori Nonaka, Group Leader, Regenerative Medicine Research & Planning Division, Rohto Pharmaceutical Co., Ltd., Japan |
| 3:15 - 3:30 | Chairperson's Closing Remarks |
| 3:30 - 3:35 | End of Day 2 |
Booking Price
Check the official website.
LINK-J provide special discount for members only. For more information, contact us by mail : contact@link-j.org or by phone: +81-3-3241-4911.
Organizer
Cell Therapy Manufacturing Asia 2020 is brought to you by informaconnect
※LINK-J is a media partner for Cell Therapy Manufacturing Asia 2020.
Contact
Check "Cell Therapy Manufacturing Asia 2020" website for appropriate contact.
Contact LINK-J for exclusive discount for LINK-J members.
